Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $479000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 85.9% to $479000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $479000.0, a 85.9% decrease, with the full-year FY2022 number at $479000.0, down 85.9% from a year prior.
  • Non-Current Deffered Revenue was $479000.0 for Q4 2022 at Denali Therapeutics, down from $3.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $57.4 million in Q4 2018 to a low of $479000.0 in Q4 2022.
  • A 5-year average of $26.2 million and a median of $31.3 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 4230.71% in 2019, then tumbled 89.15% in 2022.
  • Denali Therapeutics' Non-Current Deffered Revenue stood at $57.4 million in 2018, then dropped by 23.71% to $43.8 million in 2019, then crashed by 46.69% to $23.3 million in 2020, then plummeted by 85.43% to $3.4 million in 2021, then tumbled by 85.9% to $479000.0 in 2022.
  • Per Business Quant, the three most recent readings for DNLI's Non-Current Deffered Revenue are $479000.0 (Q4 2022), $3.4 million (Q2 2022), and $3.4 million (Q1 2022).